D S McMeekin

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. pmc A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study
    D Scott McMeekin
    University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States Electronic address
    Gynecol Oncol 138:36-40. 2015
  2. doi request reprint Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer
    Scott McMeekin
    Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA Electronic address
    Gynecol Oncol 138:18-23. 2015
  3. pmc Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents
    Katherine M Moxley
    University of Oklahoma Health Sciences Center, 4502 East 41st Street, Tulsa, Oklahoma 74135, USA
    Oncologist 15:1026-33. 2010
  4. doi request reprint A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study
    D Scott McMeekin
    Department of Obstetrics and Gynecology, Gynecologic Oncology Section, University of Oklahoma, Oklahoma City, OK 73104, USA
    Gynecol Oncol 127:356-61. 2012
  5. pmc Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    S McMeekin
    University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, 825 NE 10th Street, Oklahoma City, OK 73104, USA
    Br J Cancer 106:70-6. 2012
  6. ncbi request reprint A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer
    D Scott McMeekin
    University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 90:64-9. 2003
  7. doi request reprint Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study
    D Scott McMeekin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 112:134-41. 2009
  8. pmc A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study
    D Scott McMeekin
    Department of Gynecologic Oncology, Health Sciences Center, Ob Gyn, P O Box 26901, Williams Pavilion Room WP2470, Oklahoma City, OK 73190, USA
    Gynecol Oncol 105:508-16. 2007
  9. ncbi request reprint The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study
    D Scott McMeekin
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 106:16-22. 2007
  10. ncbi request reprint Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer
    D Scott McMeekin
    Division Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73109, USA
    Gynecol Oncol 95:157-64. 2004

Detail Information

Publications46

  1. pmc A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study
    D Scott McMeekin
    University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States Electronic address
    Gynecol Oncol 138:36-40. 2015
    ..To determine the maximum tolerated dose (MTD) of a modified paclitaxel/doxorubicin/cisplatin (TAP) regimen which incorporated intraperitoneal (IP) paclitaxel or IP paclitaxel/cisplatin in advanced endometrial cancer...
  2. doi request reprint Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer
    Scott McMeekin
    Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA Electronic address
    Gynecol Oncol 138:18-23. 2015
    ....
  3. pmc Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents
    Katherine M Moxley
    University of Oklahoma Health Sciences Center, 4502 East 41st Street, Tulsa, Oklahoma 74135, USA
    Oncologist 15:1026-33. 2010
    ..These agents alone and in combination represent a new therapeutic opportunity in endometrial carcinoma...
  4. doi request reprint A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study
    D Scott McMeekin
    Department of Obstetrics and Gynecology, Gynecologic Oncology Section, University of Oklahoma, Oklahoma City, OK 73104, USA
    Gynecol Oncol 127:356-61. 2012
    ....
  5. pmc Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
    S McMeekin
    University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, 825 NE 10th Street, Oklahoma City, OK 73104, USA
    Br J Cancer 106:70-6. 2012
    ..This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carboplatin in patients with recurrent platinum-sensitive ovarian cancer (OC)...
  6. ncbi request reprint A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer
    D Scott McMeekin
    University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 90:64-9. 2003
    ..The goal of this study was to determine response rate and evaluate toxicity of LY353381 (arzoxifene) in patients with recurrent or advanced endometrial cancer (EC)...
  7. doi request reprint Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study
    D Scott McMeekin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 112:134-41. 2009
    ..To determine the maximum tolerated dose (MTD) and feasibility of weekly cisplatin and paclitaxel chemotherapy administered concurrently with whole abdominal radiation therapy (WART) in women with high-risk endometrial cancer...
  8. pmc A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study
    D Scott McMeekin
    Department of Gynecologic Oncology, Health Sciences Center, Ob Gyn, P O Box 26901, Williams Pavilion Room WP2470, Oklahoma City, OK 73190, USA
    Gynecol Oncol 105:508-16. 2007
    ....
  9. ncbi request reprint The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study
    D Scott McMeekin
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA
    Gynecol Oncol 106:16-22. 2007
    ..To explore associations between histology and outcome in advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials...
  10. ncbi request reprint Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer
    D Scott McMeekin
    Division Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73109, USA
    Gynecol Oncol 95:157-64. 2004
    ....
  11. ncbi request reprint A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study
    D Scott McMeekin
    University of Oklahoma, Department of Gynecologic Oncology, Health Sciences Center, Ob Gyn, Oklahoma City, OK 73190, and Department of Reproductive Medicine, University Hospitals of Cleveland, OH 44106, USA
    Gynecol Oncol 106:596-603. 2007
    ....
  12. ncbi request reprint Endometrial cancer: treatment of nodal metastases
    D Scott McMeekin
    University of Oklahoma, Health Science Center, PO Box 26901, Oklahoma City, OK 73190, USA
    Curr Treat Options Oncol 4:121-30. 2003
    ..The most promising treatment option is combination therapy with sequential radiation and chemotherapy. Active chemotherapy agents in endometrial cancer are doxorubicin, cisplatin, and paclitaxel...
  13. ncbi request reprint Ovarian cancer metastatic to the brain: what is the optimal management?
    D S McMeekin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190 0001, USA
    J Surg Oncol 78:194-200; discussion 200-1. 2001
    ..To better define determinants of survival and optimal management strategies for patients with ovarian cancer and brain metastases...
  14. ncbi request reprint Analysis of FIGO Stage IIIc endometrial cancer patients
    D S McMeekin
    Department of Obstetrics-Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
    Gynecol Oncol 81:273-8. 2001
    ..The extent which adjuvant treatments contributed to the 77% 3-year survival remains to be defined. The patterns of failure suggest a possible role for combined modalities in future treatments...
  15. doi request reprint Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?
    E K Nugent
    Department of Obstetrics and Gynecology, The University of Oklahoma Health Science Center, Oklahoma City, OK, USA
    Gynecol Oncol 125:94-8. 2012
    ..Several predictive models are available which use uterine factors to stratify risk groups. Our objective was to determine how LN status affects recurrence and survival compared to uterine factors alone...
  16. ncbi request reprint Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates
    Lisa M Landrum
    Section of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, P O Box 26901, WP 2410, Oklahoma City, OK 73190, USA
    Gynecol Oncol 108:342-7. 2008
    ..The purpose of this study was to review the completion rate of patients receiving i.p. chemotherapy as first line treatment at a single institution and determine what factors prohibit completion of therapy...
  17. ncbi request reprint Nodal distribution and its significance in FIGO stage IIIc endometrial cancer
    D S McMeekin
    Department of Obstetrics-Gynecology, University of Oklahoma, Oklahoma City, Oklahoma 73190, USA
    Gynecol Oncol 82:375-9. 2001
    ..Patients with positive PALN had more extensive disease, but survival and patterns of failure were not significantly different from those with disease confined to PLN, suggesting that lymph node dissection may have a therapeutic role...
  18. ncbi request reprint Carcinosarcoma of the ovary-a case series
    Teresa L Rutledge
    University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Gynecol Oncol 100:128-32. 2006
    ..To evaluate our experience with ovarian carcinosarcoma and identify prognostic factors...
  19. ncbi request reprint A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix
    Michael L Pearl
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, NY, USA
    Gynecol Obstet Invest 64:193-8. 2007
    ..A phase II study was conducted to assess the activity and toxicity of weekly docetaxel in patients with advanced or recurrent cancer of the cervix...
  20. ncbi request reprint A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
    Teresa L Rutledge
    University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Gynecol Oncol 95:70-6. 2004
    ..To compare stages IB1 and IB2 cervical cancers treated with radical hysterectomy (RH) and to define predictors of nodal status and recurrence...
  21. ncbi request reprint Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 23:6794-5. 2005
  22. ncbi request reprint Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience
    W K Huh
    Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA
    Int J Gynecol Cancer 17:886-9. 2007
    ....
  23. doi request reprint Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis
    Kathleen N Moore
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA
    Cancer 116:5407-14. 2010
    ..This study evaluated whether progression-free interval (PFI) following primary chemotherapy (PCT) was predictive of overall survival (OS) after second-line chemotherapy in advanced/recurrent endometrial cancer (EC)...
  24. ncbi request reprint Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, PO Box 26901, Williams Pavilion 2410, Oklahoma City, OK 73190, USA
    Gynecol Oncol 108:584-90. 2008
    ....
  25. doi request reprint Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes
    Kathleen N Moore
    University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Boulevard, Oklahoma City, OK, USA
    Gynecol Oncol 108:466-71. 2008
    ..To examine surgico-pathologic outcomes following extraperitoneal para-aortic lymph node dissection (EPLND) via pfannenstiel compared to paramedian incision prior to radiation in patients with cervical cancer...
  26. doi request reprint Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
    Kathleen N Moore
    University of Oklahoma Health Sciences Center, Division of Gynecologic Oncology, Oklahoma City, Oklahoma 73103, USA
    Gynecol Oncol 110:133-9. 2008
    ..Optimal management for very elderly women (>80) is unclear. This study sought to review the experience with treating ovarian cancer in this population...
  27. doi request reprint Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?
    Kathleen N Moore
    Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA
    Cancer 115:1472-80. 2009
    ..In the current study, chemotherapy-related toxicity data were evaluated between patients aged > or = 80 years and those aged < 80 years...
  28. doi request reprint Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Gynecol Oncol 112:337-41. 2009
    ..The objective of this study is to evaluate overall survival (OS) and progression-free survival (PFS) in patients with advanced EC compared to a cohort of patients with OC matched for age and residual disease...
  29. ncbi request reprint Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma
    Kathleen N Moore
    University of Oklahoma Health Sciences Center, 920 SL Young Blvd, WP 2470, Oklahoma City, OK, USA
    Gynecol Oncol 106:498-501. 2007
    ..To evaluate the rate of vesicovaginal fistula formation and mortality in women with Stage IVA cervical carcinoma...
  30. ncbi request reprint Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era
    Lisa M Landrum
    Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Oklahoma University Health Sciences Center, PO Box 26901, WP2410, Oklahoma City, OK 73190, USA
    Gynecol Oncol 106:521-5. 2007
    ..The purpose of this study is to reassess these risk groups in patients treated in an era of contemporary management...
  31. ncbi request reprint Laparoscopic pelvic and paraaortic lymph node dissection in the obese
    Dennis R Scribner
    Division of Gynecologic Oncology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73190, USA
    Gynecol Oncol 84:426-30. 2002
    ..The aim of this study was to determine the utility of laparoscopic pelvic and paraaortic lymph node dissection in obese women...
  32. ncbi request reprint Targeted therapies for gynecologic malignancies
    Johnny Hyde
    University of Oklahoma HSC, PO Box 26901, Oklahoma City, OK 73190, USA
    Curr Treat Options Oncol 6:121-32. 2005
    ..This review covers strategies used to develop targeted agents, reviews available targeted therapies, and suggests potential roles in the treatment of gynecologic cancers...
  33. doi request reprint Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study
    D S McMeekin
    Division of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
    Gynecol Oncol 114:288-92. 2009
    ..To assess the efficacy and safety of single-agent trabectedin in women with persistent or recurrent endometrial cancer...
  34. ncbi request reprint Clinical and pathologic correlates in surgical stage II endometrial carcinoma
    David E Cohn
    Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, Ohio, USA
    Obstet Gynecol 109:1062-7. 2007
    ..To identify the surgical, pathologic, and therapeutic factors that influence outcome in patients with surgical stage II endometrial adenocarcinoma...
  35. ncbi request reprint Consolidation therapy in ovarian cancer: where do we stand?
    Daynelle D Dearnley
    University of Oklahoma, Division of Gynecologic Oncology, Oklahoma City, Oklahoma 73104, USA
    Curr Opin Obstet Gynecol 18:3-7. 2006
    ..Consolidation has been tested with multiple treatment modalities including cytotoxic chemotherapy, radiation and biological therapies. A review of recently published clinical trials is presented...
  36. doi request reprint Vulvar cancer in young women: demographic features and outcome evaluation
    Grainger S Lanneau
    Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Am J Obstet Gynecol 200:645.e1-5. 2009
    ..The objective of the study was to identify prognostic and environmental factors associated with vulvar carcinoma in young women...
  37. ncbi request reprint Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
    Cheryl A Brewer
    Division of Gynecologic Oncology, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 100:385-8. 2006
    ..This trial was conducted to evaluate the safety and efficacy of cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix...
  38. doi request reprint Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial
    Eric D Thomas
    Stephenson Oklahoma Cancer Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, United States Electronic address
    Gynecol Oncol . 2016
    ..Our primary objective was to evaluate the effectiveness of a cyanoacrylate microbial sealant (CMS) to reduce post-operative SSI following laparotomy for suspected gynecologic malignancy...
  39. ncbi request reprint Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study
    David Scott Miller
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Cancer 98:1664-9. 2003
    ..Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability and antitumor activity of a 3-day topotecan regimen...
  40. doi request reprint A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology
    David Scott Miller
    Division of Gynecologic Oncology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Room J7 124, Dallas, TX 75390 9032, USA
    Gynecol Oncol 115:443-6. 2009
    ..To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the endometrium and to determine the nature and degree of toxicity...
  41. ncbi request reprint Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone
    Todd D Tillmanns
    Department of Obstetrics and Gynecology, University of Tennessee at Memphis, 854 Jefferson Ave, Room E 102, Memphis, TN 38163, USA
    Gynecol Oncol 100:379-84. 2006
    ..A LEEP-Cone may not be necessary for all patients with traditional cone indications. This study defines populations where a single pass technique with the LEEP is appropriate...
  42. ncbi request reprint Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study
    Harry J Long
    Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Oncol 23:4626-33. 2005
    ....
  43. ncbi request reprint Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
    Harry J Long
    Mayo Clinic, Department of Medical Oncology, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905 0001, USA
    Gynecol Oncol 100:537-43. 2006
    ..The primary endpoint was overall survival (OS), with response rate, progression-free survival (PFS), and quality of life (QOL) as secondary objectives...
  44. ncbi request reprint Role of pegylated liposomal doxorubicin in ovarian cancer
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
    Gynecol Oncol 96:10-8. 2005
    ..The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin...
  45. ncbi request reprint Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?
    Scott A Kamelle
    Oklahoma Health Sciences Center, USA
    Gynecol Oncol 94:249-55. 2004
    ..To evaluate how the independent predictors of recurrence for stage IB2 cervical cancers treated with up-front radical hysterectomy apply to established risk models...
  46. ncbi request reprint Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group
    Michael A Bookman
    Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Gynecol Oncol 103:473-8. 2006
    ..Selection of a feasible sequence and schedule of carboplatin in combination with topotecan for evaluation in advanced epithelial ovarian cancer (EOC)...